Business Wire

2025 Ecolab Watermark ™ Study Reveals Hidden Impact of Artificial Intelligence

30.10.2025 13:30:00 CET | Business Wire | Press Release

Share

Ecolab, a global sustainability leader offering water solutions and services, today announced findings from its third annual Ecolab Watermark™ Study, which reports on water stewardship around the world. This year’s research highlights water’s connection to timely global trends, including new business opportunities from the rapid growth of artificial intelligence (AI) and consumer concern about its impact on vital natural resources.

According to the Watermark Study, a majority of consumers across fifteen countries understand the power demands of AI, but far fewer recognize the hidden impact of AI – the amount of water required to manufacture AI technology and operate data centers. In the United States (U.S.), just 46% of consumers acknowledge the use of water in AI operations compared to 55% recognizing the use of power. In other regions, including Asia Pacific and Latin America, the gap is even more pronounced.

“By 2050, the world will have nearly 30% more people and require 47% more energy. Water demand will continue to surge—yet by 2030, the world already faces a projected 56% water deficit,” said Christophe Beck, chairman and chief executive officer at Ecolab. “The AI boom is helping to shape this future, unleashing the potential for new business growth and transformative innovation. At the same time, every week a new data center opens, and every month a new fab comes online. While we can create more of the energy these facilities need, we cannot create more of our most vital resource – water.”

“Right now, just 20 percent of industrial wastewater is reused and less than 10 percent in the microelectronics industry. We see wastewater as an engineering flaw and a missed opportunity as a driver for business growth. At Ecolab, we believe the solution to the AI resource challenge lies within itself. By applying AI to data analytics, real-time monitoring, and temperature adjustments, we believe industrial water management systems can deliver data centers that use less water than a car wash.”

The Watermark Study reveals that most consumers agree businesses should invest in the technologies and infrastructure that mitigate the impact of AI on natural resources. It also revealed a hidden trust gap – consumers doubt that businesses will responsibly manage their water use. In fact, a majority believe smart water management, such as reusing or recycling water, should be a top priority for businesses to help address water scarcity. Yet they don’t believe that businesses and governments are using these strategies in their daily operations. Belief is particularly low in the U.S. (43% and 42%), Europe (44% and 41%), Asia Pacific (48% and 48%) and Latin America (48% and 46%).

“Global consumers recognize smart water management is essential for a resilient future, and they expect businesses to lead with both transformative technologies and transparent action to make it a reality,” said Emilio Tenuta, chief sustainability officer at Ecolab. “Businesses have an opportunity to harness the power of AI and deliver impact-driven water solutions that meet the needs of local communities, while also driving innovation and business growth.”

The Watermark Study also took a closer look at consumer perceptions of water-related extreme weather events and water availability around the world. Although concerns about water scarcity remain high, consumers are optimistic that the challenge can be addressed.

The Ecolab Watermark Study was conducted in partnership with Morning Consult in March 2025. Respondents came from a sample of general population adults based in the regions of Asia Pacific, China, Europe, Latin America, India/Middle East/Africa and the U.S. The online study included a selection of countries within each region to provide a global overview of water stewardship where it matters most.

To see the full global trends and country-specific results, please visit the interactive dashboard at watermark.ecolab.com.

About Ecolab:

A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on a century of innovation, Ecolab has annual sales of $16 billion, employs more than 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, life sciences, hospitality and industrial markets. www.ecolab.com

Follow us on LinkedIn @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.

(ECL-C)

View source version on businesswire.com: https://www.businesswire.com/news/home/20251030911280/en/

Contacts

Torry Whitney
+1-651-250-4724
MediaRelations@Ecolab.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye